Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Balakrishna Hosmane

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Clinical Drug Investigation|April 24, 2014
Pharmacokinetic and exposure-response analyses of leuprolide following administration of leuprolide acetate 3-month depot formulations to children with central precocious pubertyNael M Mostafa, Balakrishna Hosmane, Lois M Larsen, et al.
Journal of Clinical Pharmacology|October 28, 2008
ABT-335, the choline salt of fenofibric acid, does not have a clinically significant pharmacokinetic interaction with rosuvastatin in humansTong Zhu, Walid M Awni, Balakrishna Hosmane, et al.
The AAPS Journal|July 8, 2017
Application of Exposure-Response Analyses to Establish the Pharmacodynamic Similarity of a Once-Daily Regimen to an Approved Twice-Daily Dosing Regimen for the Treatment of HCV InfectionAkshanth R Polepally, Haoyu Wang, Patrick J Marroum, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2022
CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 StudyBenoit You, Vasudha Sehgal, Balakrishna Hosmane, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Clinical Drug Investigation|April 24, 2014
Pharmacokinetic and exposure-response analyses of leuprolide following administration of leuprolide acetate 3-month depot formulations to children with central precocious pubertyNael M Mostafa, Balakrishna Hosmane, Lois M Larsen, et al.
Journal of Clinical Pharmacology|October 28, 2008
ABT-335, the choline salt of fenofibric acid, does not have a clinically significant pharmacokinetic interaction with rosuvastatin in humansTong Zhu, Walid M Awni, Balakrishna Hosmane, et al.
The AAPS Journal|July 8, 2017
Application of Exposure-Response Analyses to Establish the Pharmacodynamic Similarity of a Once-Daily Regimen to an Approved Twice-Daily Dosing Regimen for the Treatment of HCV InfectionAkshanth R Polepally, Haoyu Wang, Patrick J Marroum, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2022
CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 StudyBenoit You, Vasudha Sehgal, Balakrishna Hosmane, et al.
Pageof 2